Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-026307
Filing Date
2021-05-11
Accepted
2021-05-11 08:15:44
Documents
50
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q 2021 rapt-10q_20210331.htm 10-Q 1810530
2 EX-31.1 rapt-ex311_6.htm EX-31.1 18157
3 EX-31.2 rapt-ex312_8.htm EX-31.2 18157
4 EX-32.1 rapt-ex321_7.htm EX-32.1 14772
  Complete submission text file 0001564590-21-026307.txt   5084969

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT rapt-20210331.xml EX-101.INS 957309
6 XBRL TAXONOMY EXTENSION SCHEMA rapt-20210331.xsd EX-101.SCH 32906
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rapt-20210331_cal.xml EX-101.CAL 38348
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rapt-20210331_def.xml EX-101.DEF 99415
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE rapt-20210331_lab.xml EX-101.LAB 277303
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rapt-20210331_pre.xml EX-101.PRE 202338
Mailing Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 489-9000
RAPT Therapeutics, Inc. (Filer) CIK: 0001673772 (see all company filings)

EIN.: 473313701 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38997 | Film No.: 21909715
SIC: 2834 Pharmaceutical Preparations